Patent ID: 11896615
Assignee: JUNO THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  G | IPC A  C  G

Claim 17:
18. The method of claim 1, wherein the engineered cell further comprises a modification of expression of a molecule associated with IDO-mediated immunosuppressive signaling, associated with sensing or responding to tryptophan starvation or insufficiency, or associated with sensing or responding to kynurenine-mediated immuno-suppression in the cell, wherein the molecule is selected from the group consisting of:
mTOR, protein kinase C theta (PKC-Θ);
rBAT (SLC3A1), CD98 heavy chain (4F2hc; SLC3A2), L-type Amino Acid Transporter 1 (LAT1; SLC7A5), LAT2 (SLC7A8), Asc-type amino acid transporter 1 (Asc-1; SLC7A10), Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+)(ATB0,+; SLC6A14), Sodium-dependent neutral amino acid transporter B(0)AT1 (B(0)AT1; SLC6A19), Monocarboxylate transporter 10 (TAT1; SLC16A10), proton-assisted amino-acid transporter 4 (PAT4; SLC36A4) or a portion thereof;
GCN2 kinase, BLIMP-1, aryl hydrocarbon receptor (AHR), AHR nuclear transporter (ARNT), eukaryotic translation initiation factor 2 α (eIF2α), activating transcription factor 4 (ATF4), CCAAT/enhancer binding protein-homologous protein (CHOP), Gadd45α, Herp, 4E-BP1, eIF4G, JAK1, NFκB-2, FK506-BP8, and IFNγ-R2.